



First-half results in line with the Company's buoyant development

- *Strong financial structure: cash position of €13.6m at end-August 2015*
- *Progress made in R&D programmes and oral presentation on preclinical in vivo hearing loss recovery at Neuroscience 2015*
- *Strengthening of the Company's teams*

Montpellier, October 5, 2015 (FR0012596468 – ALSEN / PEA-PME eligible) – Sensorion, a biotech specialising in the treatment of inner ear diseases, today announces its results for the first half to June 30, 2015 as well as recent developments.

Laurent Nguyen, CEO of Sensorion, comments: *"Financial results for the first half of 2015 are in line with the development plan presented to the financial community at the time of our IPO in April 2015. That operation, together with the additional funds raised in July, has provided us with a financial structure that is capable of accelerating the development of our three drug candidate programmes. This is a leveraging point for Sensorion, a unique company in the inner-ear segment, and we are also delighted to have strengthened our team."*

Financial results for the first half of 2015

The Company's financial statements for the six months ended June 30, 2015, prepared under IFRS, have been the subject to a limited review by its statutory auditors and were approved by the Board on September 28, 2015.

They highlight an increase in operating costs consistent with Sensorion's Research and Development activities, a controlled cash management and, finally, a healthy and solid financial structure.

The summarized income statement at June 30, 2015 is as follows:

<i>In euros - IFRS</i>	30.06.2015	30.06.2014
Operating income	490,290	239,225
Research & Development expenses	1,548,488	918,772
General and Administrative expenses	431,498	393,082
Total operating expenses	1,979,986	1,311,854
Operating profit / loss	-1,489,696	-1,072,629
Financial profit / loss	-36,776	-140,085
Net profit / loss	-1,526,472	-1,212,715

At June 30, 2015, Sensorion's **operating income**, consisting of Research Tax Credit (€358 thousand), subsidies (€92 thousand) and repayable advances (€40 thousand), totalled €490 thousand, up 105% from June 30, 2014.

Operating expenses increased from €1.3 million at June 30, 2014 to approximately €2.0 million at June 30, 2015, notably as a result of the scaling up of preclinical and clinical developments with regard to the Company's drug candidates. R&D expenses accounted for over 78% of total operating expenses.

The **operating loss** at June 30, 2015 was -€1.5 million, compared with -€1.1 million at June 30, 2014.

After taking the **financial loss** (-€37 thousand) into account, the **net loss** was -€1.5 million at June 30, 2015 compared to a net loss of -€1.2 million at June 30, 2014.

At June 30, 2015, the Company had a staff of 14.

At June 30, 2015, Sensorion had cash and cash equivalents of €6.7 million, versus €0.7 million a year earlier. This total includes €1.2 million from a rights issue carried out in February 2015 within the framework of the investment agreement between Sensorion, InnoBio-Bpifrance and Inserm Transfert Initiative as well as the net proceeds (after deduction of transaction costs) of the Initial Public Offering carried out on Alternext in April 2015 (€8 million), less cash expenditures of €2 million for the period.

At the end of July 2015, Sensorion further boosted its available cash through an €8 million international private placement. Consequently, its cash position reached €13.6 million at the end of August 2015.

Solid operational breakthroughs since January 1, 2015

- SENS-111: completion of the first stage of the phase 1b clinical trial on SENS-111 and continuation of the second stage. The Company expects announcing the final results during the fourth quarter of 2015. A phase 2 clinical trial should start during the second quarter of 2016, in line with the schedule announced at the time of the IPO.
- SENS-200: positive results of a preclinical study on hearing loss recovery following an acoustic trauma have attracted interest from the international scientific community. They will be presented at the 45th Society for Neuroscience Annual Meeting, which will take place in Chicago from October 17 to 21, 2015. These results pave the way for a phase 2 clinical trial (potentially a phase 2/3 clinical trial in the case of an orphan indication) in hearing impairments for this second programme.
- Sensorion's administrative and R&D teams have been brought together on new central premises in Montpellier that meet the pharmaceutical industry's most stringent standards, and notably have International AAALAC (Association for Assessment and Accreditation of Laboratory Animal Care) accreditation.
- Mr. Patrick Langlois has been appointed as Director and Chairman of the Board, Mr. François Thomas as Director and Dr. Pierre Attali as Chief Medical Officer. The administrative and financial department has been strengthened by Mr. Paul Bikard.

Upcoming events attended by the Company

- **Participation in the Portzamparc Biotech Seminar**, on October 14, 2015 in Paris
- **Presentation of an abstract at Neuroscience 2015**, on October 19, 2015 in Chicago
- **Participation in the Salon Actionaria trade fair**, on November 20-21, 2015 in Paris



About Sensorion

Spun off from Inserm (the French institute of health and medical research) in 2009, Sensorion is a biotech that specialises in the treatment of pathologies of the inner ear such as acute vertigo, tinnitus and hearing loss. Backed by its pharmaceutical R&D experience and a comprehensive technology platform, Sensorion is developing three drug candidate programmes for treating the symptoms of vertigo or tinnitus, for preventing complications associated with progressive lesions in the inner ear and for preventing the toxicity of chemotherapy in the inner ear. Based in Montpellier, southern France, Sensorion has a portfolio of 7 patent

families, employs 15 staff and receives financial support from Bpifrance, through the InnoBio fund, and Inserm Transfert Initiative.

For more information: www.sensorion-pharma.com

Contacts

Sensorion

Laurent Nguyen
CEO

contact@sensorion-pharma.com

Tel: +33 (0)4 67 20 77 30

Name: **SENSORION**

ISIN code: **FR0012596468**

Ticker: **ALSEN**

NewCap

Dusan Oresansky / Emmanuel Huynh
Investor Relations & Strategic communications

sensorion@newcap.fr

Tel: +33 (0)1 44 71 94 92

ALSEN
LISTED
ALTERNEXT



Disclaimer

This press release contains certain forward-looking statements concerning Sensorion and its business. Such forward-looking statements are based on assumptions that Sensorion considers to be reasonable. However, there can be no assurance that such forward-looking statements will be verified, which statements are subject to numerous risks, including the risks set forth in the prospectus on which the French Financial Market Authority (AMF) granted its visa n° 15-114 on March 27, 2015 and to the development of economic conditions, financial markets and the markets in which Sensorion operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Sensorion or not currently considered material by Sensorion. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Sensorion to be materially different from such forward-looking statements.

This press release and the information that it contains do not constitute an offer to sell or subscribe for, or a solicitation of an offer to purchase or subscribe for, Sensorion shares in any country. The communication of this press release in certain countries may constitute a violation of local laws and regulations. Any recipient of this press release must inform oneself of any such local restrictions and comply therewith.